Title :

Modulation of host defence against bacterial and viral infections by omega-3 polyunsaturated fatty acids.

Author(s) :

Husson, Marie-Odile [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Ley, Delphine [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Portal, Céline [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Gottrand, Madeleine [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Hueso, Thomas [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Desseyn, Jean-Luc [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
gottrand, frederic [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]

Journal title :

The Journal of infection

Abbreviated title :

J Infect

Volume number :

73

Pages :

523-535

Publication date :

2016-12

ISSN :

1532-2742

English keyword(s) :

Administration
Oral
Bacterial Infections
Chronic Disease
Citrobacter rodentium
Dietary Supplements
Fatty Acids
Omega-3
Helicobacter hepaticus
Herpes Simplex
Humans
Inflammation
Mycobacterium tuberculosis
Staphylococcal Infections
Staphylococcus aureus
Virus Diseases
Anti-inflammatory
Immunomodulatory
Infection
Outcome
Prevention
n-3 LC-PUFA

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Although n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) are used widely in the treatment of chronic inflammatory diseases, their effect in infectious disease requires a particular attention. The present article ...
Show more >Although n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) are used widely in the treatment of chronic inflammatory diseases, their effect in infectious disease requires a particular attention. The present article discusses their anti-inflammatory and immune properties involved in the host defence and presents a systematic review of the effects of their oral administration on the prevention and outcome of experimental and clinical infections. At a dose corresponding to an human dose of 500 mg/day, n-3 LC-PUFAs intake is beneficial against experimental infections caused by extracellular pathogens including Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus by reducing inflammation, and reduces the incidence of pneumococcal infections in the elderly, but at 2-4-fold higher doses as occurs in some human intervention and/or during long-term it becomes detrimental in intestinal infections with Citrobacter rodentium or Helicobacter hepaticus by exacerbating anti-inflammatory response. They are also harmful against infections caused by intracellular pathogens as Mycobacterium tuberculosis, Salmonella, Influenza virus and Herpes simplex virus by affecting the immune cell response. The effects of n-3-LC-PUFAs on infections depend on the pathogen and the n-3 LC-PUFA dose and timing. Caution should be recommended for high-dose and long-term supplementation in humans.Show less >

Language :

Anglais

Audience :

Non spécifiée

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2019-07-09T13:47:42Z
2019-07-10T09:05:59Z
2021-05-18T13:18:49Z